Biz News Today

Bristol-Myers Squibb Announces Dividend

June 9, 2010

Original Source

Bristol-Myers Squibb Posts Data Update on BMS-901608, an anti-CS-1 Antibody Under Investigation for the Treatment of Multiple Myeloma

June 8, 2010

Original Source

Bristol-Myers Squibb to Present at the Goldman Sachs Global Health Care Conference

June 8, 2010

Original Source

Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®1

June 7, 2010

Original Source

SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

June 5, 2010

Original Source

Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma

June 5, 2010

Original Source

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

May 27, 2010

Original Source

Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer

May 21, 2010

Original Source

Bristol-Myers Squibb to Present Data on 13 Oncology Compounds During 2010 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2010

Original Source

Bristol-Myers Squibb to Present at Citi Global Health Care Conference

May 19, 2010

Original Source

National AIDS Fund Announces Major Grants, Enabling More Than 35 Community-Based Organizations to Help Improve Access to HIV Care in their Communities

May 13, 2010

Original Source

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Health Care Conference

May 10, 2010

Original Source

Bristol-Myers Squibb Announces Authorization of Up to $3 Billion Share Repurchase Program

May 4, 2010

Original Source

Bristol-Myers Squibb Receives Complete Response Letter from FDA for Belatacept

May 1, 2010

Original Source

Bristol-Myers Squibb to Present at Deutsche Bank Conference

April 30, 2010

Original Source

Bristol-Myers Squibb Invites Public to Listen to Webcast of 2010 Annual Meeting

April 30, 2010

Original Source

Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter

April 29, 2010

Original Source

New Data on the Use of Investigational Agent Belatacept in Kidney Transplant Recipients to Be Presented at 2010 American Transplant Congress

April 28, 2010

Original Source

Bristol-Myers Squibb to Announce Results For the First Quarter 2010 on April 29

April 22, 2010

Original Source

Bristol-Myers Squibb Receives LEED® Silver Certification for its Biologics Manufacturing Facility in Devens, Massachusetts

April 21, 2010

Original Source

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Posts Data Update on BMS-901608, an anti-CS-1 Antibody Under Investigation for the Treatment of Multiple Myeloma

Bristol-Myers Squibb to Present at the Goldman Sachs Global Health Care Conference

Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®1

SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer

Bristol-Myers Squibb to Present Data on 13 Oncology Compounds During 2010 American Society of Clinical Oncology (ASCO) Annual Meeting

Bristol-Myers Squibb to Present at Citi Global Health Care Conference

National AIDS Fund Announces Major Grants, Enabling More Than 35 Community-Based Organizations to Help Improve Access to HIV Care in their Communities

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Health Care Conference

Bristol-Myers Squibb Announces Authorization of Up to $3 Billion Share Repurchase Program

Bristol-Myers Squibb Receives Complete Response Letter from FDA for Belatacept

Bristol-Myers Squibb to Present at Deutsche Bank Conference

Bristol-Myers Squibb Invites Public to Listen to Webcast of 2010 Annual Meeting

Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter

New Data on the Use of Investigational Agent Belatacept in Kidney Transplant Recipients to Be Presented at 2010 American Transplant Congress

Bristol-Myers Squibb to Announce Results For the First Quarter 2010 on April 29

Bristol-Myers Squibb Receives LEED® Silver Certification for its Biologics Manufacturing Facility in Devens, Massachusetts

Biz News Today Accepts Guest Posts

Recommended Sites